At a glance
ClinicalIndex Comparison RecordPhase 3Active· 730 enrolled
Drug / intervention
Durvalumab +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients With Limited Stage Small Cell Lung Cancer Who Have Not Progressed Following Concurrent Chemoradiation Therapy (ADRIATIC)
In Brief
A Phase 3 clinical trial evaluating Durvalumab, Tremelimumab, and 1 other intervention for Small Cell Lung Cancer. Active but no longer recruiting, targeting 730 participants across 183 sites in 19 countries.
Detailed Summary
This is a Phase III, Randomized, Double-blind, Placebo-controlled, Multi-center, International Study of Durvalumab or Durvalumab and Tremelimumab as Consolidation Treatment for Patients with LS-SCLC Who Have Not Progressed Following Concurrent Chemoradiation Therapy
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsSmall Cell Lung Cancer
CountriesArgentina, Belgium, Canada, China, Czechia, Germany, India, Italy, Japan, Netherlands, Poland, Russia, South Korea, Spain, Taiwan, Turkey (Türkiye), United Kingdom, United States, Vietnam
Collaborators--
Timeline
Phase 3Active
201920202021202220232024202520262027
Enrollment StartSep 2018
First PostedOct 2018
Primary CompletionJan 2024
TodayJul 2026
Study CompletionOct 2026
First PostedOct 11, 2018
Enrollment StartSep 27, 2018
Primary CompletionJan 15, 2024
Study CompletionOct 23, 2026
TodayJul 2, 2026
Enrollment to primary: 5.3 yearsPosted 7.7 years ago
Interventions
Durvalumabdrug
Durvalumab IV (intravenous infusion)
Tremelimumabdrug
Tremelimumab IV (intravenous infusion)
Placeboother
Placebo IV (intravenous infusion)